Pneumonic Tularemia in Rabbits Resembles the Human Disease as Illustrated by Radiographic and Hematological Changes after Infection by Reed, Douglas S. et al.
Pneumonic Tularemia in Rabbits Resembles the Human
Disease as Illustrated by Radiographic and
Hematological Changes after Infection
Douglas S. Reed
1*, Le’Kneitah Smith
1, Tammy Dunsmore
1, Anita Trichel
1, Luis A. Ortiz
2, Kelly Stefano
Cole
1, Eileen Barry
3
1Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 2Department of Environmental & Occupational Health,
University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 3Center for Vaccine Development, University of Maryland, Baltimore, Maryland, United States
of America
Abstract
Background: Pneumonic tularemia is caused by inhalation of the gram negative bacterium, Francisella tularensis. Because of
concerns that tularemia could be used as a bioterrorism agent, vaccines and therapeutics are urgently needed. Animal
models of pneumonic tularemia with a pathophysiology similar to the human disease are needed to evaluate the efficacy of
these potential medical countermeasures.
Principal Findings: Rabbits exposed to aerosols containing Francisella tularensis strain SCHU S4 developed a rapidly
progressive fatal pneumonic disease. Clinical signs became evident on the third day after exposure with development of a
fever (.40.5uC) and a sharp decline in both food and water intake. Blood samples collected on day 4 found lymphopenia
and a decrease in platelet counts coupled with elevations in erythrocyte sedimentation rate, alanine aminotransferase,
cholesterol, granulocytes and monocytes. Radiographs demonstrated the development of pneumonia and abnormalities of
intestinal gas consistent with ileus. On average, rabbits were moribund 5.1 days after exposure; no rabbits survived
exposure at any dose (190–54,000 cfu). Gross evaluation of tissues taken at necropsy showed evidence of pathology in the
lungs, spleen, liver, kidney and intestines. Bacterial counts confirmed bacterial dissemination from the lungs to the liver and
spleen.
Conclusions/Significance: The pathophysiology of pneumonic tularemia in rabbits resembles what has been reported for
humans. Rabbits therefore are a relevant model of the human disease caused by type A strains of F. tularensis.
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Introduction
Francisella tularensis, a gram negative coccobacillus that can cause
disease in a number of animals including amoeba, is the causative
agent of tularemia [1,2]. Strains of F. tularensis are divided into four
subspecies; the most virulent are subspecies tularensis (also called
type A), followed by holarctica (also called type B) [2]. Subspecies
mediasiatica and novicida are not thought to cause human disease. In
humans, F. tularensis can cause a spectrum of disease that is largely
dictated by the route of infection; the most virulent form is
pneumonic tularemia, which can cause severe morbidity/mortality
at even very low doses as low as 10 CFU [3]. Prior to the
introduction of a live, attenuated vaccine, F. tularensis was among
the most common laboratory-acquired infections [4]. Both the
United States (prior to 1969) and the former Soviet Union
developed F. tularensis as a biological weapon [1,2]. For these
reasons, F. tularensis is considered a Category A select agent by the
U.S. Department of Health & Human Services [5]. After the
anthrax letters in 2001, there was renewed concern that terrorists
or rogue nations could be developing biological weapons including
tularemia. A vaccine was developed in the 1950’s and 60’s against
tularemia using an attenuated strain of the holarctica subtype which
is named the live vaccine strain (LVS); LVS provided partial
protection of humans and nonhuman primates against aerosol
challenge with a type A strain of F. tularensis [3,6]. LVS is available
as an Investigational New Drug (IND) for at-risk personnel but is
not considered likely to be licensed because the nature of the
attenuation is unknown [7]. Nevertheless, efforts are underway to
develop and test a new lot of LVS as a potential vaccine, at least
for at-risk laboratory personnel [8,9].
Although cases of tularemia are reported every year, the
number of cases is typically quite small and most outbreaks involve
the more ubiquitous but less virulent holarctica subtype. Outbreaks
of pneumonic tularemia involving a type A strain are fairly rare.
Human clinical trials to determine efficacy sufficient to support
licensure of a vaccine or therapeutic will therefore be ethically and
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protection against F. tularensis will only be possible through the use
of the FDA’s Animal Rule. The Animal Rule requires the use of at
least one well-characterized animal model that is relevant to the
human disease and in which the mechanism of protection is
understood and shown to be similar in humans [10]. It is
commonly assumed that to meet the FDA’s requirements will
require at least two animal models. Mice have been the most
extensively used in studies of tularemia; however, there are a
number of concerns regarding the use of mice as a model for
pneumonic tularemia to support licensure by the Animal Rule. In
particular, mice are very susceptible to strains of F. tularensis,
including strains that are attenuated in humans and nonhuman
primates such as F. novicida and the live vaccine strain (LVS) [11].
Further, it is difficult to elicit good protection in mouse models
against aerosol challenge virulent F. tularensis strains at robust
challenge doses. These findings suggest that different mechanisms
may be involved both in the pathogenesis of F. tularensis infection in
mice and the protection elicited by vaccines compared to what
occurs in humans. Nonhuman primates (NHP) are a relevant
model of the human disease and are protected against respiratory
challenge with virulent strains of F. tularensis after vaccination with
LVS. However, they are expensive and difficult to work with in
numbers sufficient to generate statistical significance. Particularly
for tularemia vaccines, animal models are needed that are more
relevant than the mouse to screen candidate vaccines prior to
studies with NHP.
Tularemia is also known as rabbit fever and F. tularensis was first
isolated from a rabbit. An outbreak of pneumonic tularemia in
Martha’s Vineyards was termed ‘lawnmower tularemia’ after it
was revealed that the outbreak resulted from mowing over rabbit
dens and possibly infected carcasses [12]. Very little has been done
experimentally in rabbits to study the pathology of F. tularensis
infection or the relevance to the human disease. A British study
in the 1970’s established that the pathology of experimental
pneumonic tularemia in rabbits was similar to that reported in
humans and nonhuman primates [13]. A subsequent study found
that although LVS was indeed attenuated in rabbits, it was unable
to protect the rabbits against an aerosol challenge with a virulent
strain of F. tularensis [14]. More recently it was reported that LVS
was immunogenic in rabbits as seen by the production of a strong
antibody response but unfortunately that study did not include a
challenge component [15]. Accordingly, these studies were
conducted to determine whether rabbits might be a relevant
model of the human disease suitable for evaluation of vaccines or
therapeutics.
Results
To develop a rabbit model of pneumonic tularemia, 20 young
female NZW rabbits were exposed to aerosols of F. tularensis strain
SCHU S4 at doses ranging from 190 cfu up to 5.4610
4 cfu
(Table 1). Rabbits were monitored daily for changes in body
temperature, and weight, as well as clinical signs indicative of
disease including changes in behavior, anorexia, dehydration, and
respiratory distress. Rabbits that became moribund were eutha-
nized promptly, however, as noted in Table 1, 7 of the 20 rabbits
were found dead prior to meeting the established criteria for being
moribund. To simplify the analysis of the fever and weight loss and
to look for trends based on dose, the rabbits were divided into
three groups based on dose: low (,3000 cfu; n=9), medium
(3000–9,000 cfu; n=7) and high ($10,000 cfu; n=4). Time to
death was extended by 1–2 days for two rabbits in the low dose
group relative to other rabbits, giving a longer time to death for
the low dose group (5.1 d61 d) compared to the other dose groups
(4.9 d60.4 d for the medium dose and 4.8 d60.5 d for the high
dose). The difference in time to death between the low dose group
and the medium and high dose groups was not statistically
significant using a two-tailed Student’s t-test (p=0.51 and p=0.40,
when comparing the low dose group to the medium and high dose
groups, respectively).
A febrile response (designated as body temperature .40uC) was
first seen in rabbits 2–3 days after exposure (Figure 1A). On
average, temperatures remained elevated for 48–72 hours, at
which point they began to decline in the medium and higher dose
animals. The two rabbits at lower doses that survived out to days 6
and 7 had a persistent fever until the animals succumbed. Table 1
shows the maximum body temperature observed prior to death
for all of the rabbits. Regardless of dose, the maximum body
temperature observed was similar across the three dose groups
(41.3uC, 41.0uC, and 41.3uC for the low, medium, and high doses
respectively).
Similarly, weight loss was first detected in rabbits regardless of
dose group on day 3 (Figure 1B). Rabbits continued to lose weight
until they succumbed to the infection, except for the two rabbits
that survived out to days 6 and 7 and which started to recover
some weight prior to ultimately succumbing to the infection. The
maximum weight loss observed for each rabbit prior to death is
shown in Table 1. Animals in the low dose group lost more weight
prior to succumbing to the infection (10.7%62.9% compared to
7.4%63.3% and 6.4%63.1% for the medium and high dose
groups, respectively). These differences were statistically significant
between the low and medium dose groups (p=0.05) but did not
rise to the level of significance (p=0.06) between the low and high
dose groups.
Six rabbits used in these studies underwent more extensive
monitoring to determine other parameters associated with the
outcome of pneumonic tularemia. As shown in Figure 2, both food
and water intake decreased between days 2 and 3 after exposure,
at the same time that fever onset and weight loss was also
observed. Intake continued to decline on day 5, with five of the six
rabbits consuming no food or water. Due to other clinical signs,
those five rabbits were determined to be moribund and
subsequently euthanized on day 5; the remaining rabbit did
consume some food on day 5 but by day 6 that rabbit had
decreased food and water intake to zero. Due to other clinical signs
the final rabbit was determined to be moribund on day 6 and was
euthanized.
These six rabbits were also bled to assess hematological
changes associated with pneumonic tularemia, beginning two
days prior to infection with F. tularensis; all of the rabbits were
bled on day 4 and then again immediately prior to being
euthanized on day 5 (n=5) or day 6 (n=1). Bacteremia was
assessed by plating on CHA plates. Surprisingly, only one of the
six rabbits was positive and that was the rabbit that survived to
day 6; it was only positive on day 6 and the levels were very low,
6.1610
2 cfu/ml of blood (data not shown). No difference was
seen by incubating the blood in 0.1% sodium deoxycholate prior
to diluting and plating on CHA. White blood cell counts dropped
on day 4 relative to the pre-exposure baseline and then more
dramatically on day 5 postexposure (Figure 3A). Further analysis
indicated that this decline in WBC was almost entirely due to a
drop in the number of mononuclear cells with lymphocytes
decreasing on day 4 and lymphocytes and monocytes on day 5.
Granulocyte counts were essentially unchanged on day 4 and
decreased on day 5. Coagulopathies have not been reported
in human cases of tularemia, so it was surprising to see the
significant decrease in platelet counts on day 4 compared to
Pneumonic Tularemia in Rabbits
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animals examined, only one animal had detectable platelets after
day 4. Platelets from that animal had an elevated MPV on day 6
(11) compared to day 4 (7.7) which is suggestive of a release of
immature platelets from the bone marrow. The other hemato-
logical parameters evaluated (RBC, HGB, HCT, MCV, MCH,
MCHC, RDWc, PCT, and PDWc) showed little or no change
after exposure (data not shown).
Table 1. Relationship between inhaled dose and disease in rabbits infected with aerosolized F. tularensis.
Inhaled Dose Max Temp. Max % Time to Death Found Dead or Euthanized?
1
Weight Lost
£
1.9E+02 41.8 27.7 7 E
7.3E+02 41.1 210.9 4 E
8.3E+02 41.2 28.8 5 FD
1.1E+03 40.8 211.4 5 E
1.1E+03 41.4 213.9 5 E
1.4E+03 41.7 212.5 5 E
1.5E+03 41.5 26.2 4 E
1.8E+03 41.2 214.0 6 E
2.9E+03 41.5 24.2 5 FD
3.3E+03 40.3 26.1 5 E
4.2E+03 41.4 22.0 4 E
6.6E+03 41 25.9 5 FD
7.3E+03 41.3 211.1 5 FD
7.5E+03 41.1 211.1 5 E
8.4E+03 40.7 29.1 5 E
8.6E+03 40.6 29.4 5 FD
1.0E+04 41.1 22.8 4 FD
1.7E+04 41.5 26.3 5 E
2.0E+04 40.9 26.3 5 FD
5.4E+04 41.7 210.4 5 E
£Weight lost compared to pre-exposure weight.
1FD=found dead; E=euthanized when moribund.
doi:10.1371/journal.pone.0024654.t001
Figure 1. Fever and weight loss after inhalation of F. tularensis. NZW rabbits were exposed to low (,3000 cfu, solid lines), medium (3000–
9000 cfu, dashed lines), or high (.9000 cfu, dotted lines) presented doses of F. tularensis SCHU S4 and monitored for changes in body temperature
(A) and weight (B). Graphs show averaged values for each timepoint postexposure with error bars representing the standard deviation.
doi:10.1371/journal.pone.0024654.g001
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samples as a non-specific measure of inflammation and C-reactive
protein levels (Figure 4A). Pre-exposure ESR levels were between
0 and 1 mm, as expected. ESR levels were increased substantially
on day 4, ranging from 11 to 53, with the average 40. Not
surprisingly, this difference was statistically significant from the
pre-exposure baseline (p=0.002). The ESR average increased still
further, peaking on day 5 at 60 mm. Similarly, serum cholesterol
and alanine aminotransferase (ALT) levels were elevated on day 4
and even more noticeably on day 5 (Figure 4 B and C); these
differences were also significant compared to pre-exposure
baseline levels (p=0.05 and p=0.02 for ALT and cholesterol,
respectively). Other liver parameters (ALP, GGT, BA, TBIL,
ALB, and BUN) evaluated did not show remarkable or consistent
differences between baseline and post-exposure blood samples in
all animals (data not shown).
The progression of pneumonic tularemia in the rabbits was also
assessed by x-rays and gross pathological evaluation of euthanized
rabbits. Figure 5 shows the chest x-rays and corresponding gross
lung pathology for three representative rabbits taken on 4
(Figure 5A & B) or 6 (Figure 5C) days after infection. Prominent
in all three images are areas of parenchymal consolidation and loss
of lung volume: Figure 5A shows collapse of right upper lobe with
upward expansion of right lower lobe. The x-rays images of the
lung show areas of patchy (best exemplified in Figures 5B and C)
parenchymal consolidation and prominent air bronchograms are
present suggesting the presence of pneumonia. As a result of these
abnormalities, the margins of the heart and diaphragm are erased
instead of clear. Supporting these findings, the lungs removed from
these animals show numerous distinct areas of hemorrhage
(Figure 5E) and subpleural areas of nodular pearl like consolida-
tion (Figure 5D & 5F).
Radiographs of the abdominal regions show considerable
changes 4 days after infection, including abnormal gas distribution
with distension of the stomach as well as of the small and large
intestines (Figure 6, A & B) suggesting the presence of ileus.
Pictures taken at necropsy confirm the gastric distension and
evidenced the presence of multiple, small white foci in the small
(Figure 6C) and large intestines where they were closely associated
with hemorrhage of the serosa (Figure 6D). Similar white foci were
also seen in the kidneys (data not shown). All necropsied rabbits
showed evidence of hepatosplenomegaly; the weight of the liver
and spleen relative to the body weight of the infected rabbits (3.3%
and 0.12%, respectively) was nearly 50% more than for a healthy
female rabbit of equivalent age [16]. Spleens from infected
rabbits show extensive necrosis and were darker in color than
normal spleens and demonstrated extensive white small nodules
(Figure 6E). Livers were smooth in appearance but not coloration,
with a mottled pattern of dark and light foci (Figure 6F).
Samples of liver, spleen and lung taken at necropsy were
homogenized and dilutions plated to determine the extent of
bacterial dissemination to these tissues; the results are shown in
Figure 7 plotted on a log10 scale. The concentration of bacteria in
all three tissues was highly variable between individual rabbits,
particularly in the spleen. In both the spleen and liver, the
concentration of bacteria was 2–3 logs higher in rabbits that were
euthanized compared to those that were found dead. In the spleen,
the average was 7.8610
7 cfu/g for euthanized rabbits as
compared to an average of 6.0610
4 cfu/g for rabbits that were
found dead. In spleens from three of the animals found dead no
counts were obtained. In the liver the average was 2.5610
5 cfu/g
in euthanized rabbits compared to 2.1610
3 in rabbits found dead.
In the lungs, in contrast, there was considerably more overlap
between concentrations from rabbits that were euthanized or
found dead; the average cfu/g from the lungs were 2.5610
5 for
euthanized rabbits and 6.0610
4 for rabbits found dead. However,
because of the variability in the concentration of F. tularensis, none
of the differences were statistically significant between rabbits that
were euthanized or found dead for any of the organs assayed.
Discussion
The data presented here detail the disease course and outcome of
pneumonic tularemia following infection with type A strain SCHU
S4 in New Zealand White rabbits, a potential model of the human
disease. The value of the current experimental model is predicated
on its ability to reproduce the key patho-physiological events of the
Figure 2. Rabbits reduce food and water intake after inhalation of F. tularensis. Food (A) and water (B) intake was measured daily for
6 NZW rabbits exposed to aerosolized SCHU S4. Graphs show values for individual rabbits (gray circles) and averaged data (black bars) for each day
after exposure.
doi:10.1371/journal.pone.0024654.g002
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(A), lymphocytes (B), monocytes (C), granulocytes (D), and platelets (E). Graphs show counts for individual rabbits (gray circles) and averaged data
(black bars) for each time point after exposure when blood was drawn (days 22, 2, 4, 6, and at euthanasia).
doi:10.1371/journal.pone.0024654.g003
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well with what has been reported in human cases of pneumonic
tularemia, including fever, weight loss, elevations in ALT and ESR,
leukopenia, and radiographs detailing the development of bibasilar
pneumonia [1,3,12,17]. Radiographs demonstrating the excess gas
distension of the gastrointestinal system in the rabbits could
correspond with reports in humans of abdominal pain, diarrhea,
and anorexia. In keeping with this observation, we noted a
pronounced decrease in food and water intake by the rabbits at
the same time that the initial clinical signs were reported. Ileus has
not been reported in humans infected with tularemia and is likely a
result of the cessation of eating and drinking in rabbits. Whether it is
important in the outcome of the infection in rabbits is not clear and
further work is needed to determine whether this is a critical
difference in the pathophysiology of tularemia in rabbits and
humans. Necropsy findings supported the x-ray findings in both the
lungs and intestines and also demonstrated widespread dissemina-
tion of the bacteria and hepatosplenomegaly in the rabbits which
has been reported in human tularemia [18]. The gross pathology of
the lungs suggest at least two different processes in the rabbits, one
with nodular lesions and one more hemorrhagic. The differences
seen do not appear to be a result of dose or time to death. It is
unclearwhyweareseeingmultipleprocessesinthelung,however,it
should be noted that NZW rabbits are not completely inbred so this
may be partly due to genetic differences between rabbits.
Although F. tularensis was first isolated from a rabbit and
tularemia is also known as ‘rabbit fever’, there have been few
studies detailing experimental infection with F. tularensis in rabbits,
particularly for infection via the respiratory tract. Baskerville &
Hambleton examined the pathogenesis of pneumonic tularemia in
NewZealand White rabbits after exposure to aerosolized F. tularensis
strain SCHU S4 [13]. These investigators reported calculated
inhaled retention doses between 2610
4–4610
8 cfu; however, they
did not report how the ‘calculated inhaled retention dose’ was
calculated. Our doses are calculated as presented doses, which are
represented as the total amount of bacteria inhaled [19]. The
retained dose typically represents the amount of bacteria which
deposit in the lung and are not cleared by the mucociliary escalator
or other mechanisms, and as such is some fraction of the presented
dose. Therefore the doses reported by Baskerville & Hambleton are
at least 1–4 log10 cfu higher than the challenge doses we delivered in
these studies. Importantly, our study demonstrates that rabbits are
susceptible to very low doses of tularemia without appreciable
increasesintimetodeath.OverthecourseofthestudyBaskerville&
Hambleton noted pathological changes first in the lung, progressing
into the cervical and bronchial lymph nodes, the liver, and the
spleen. Similar to the results reported here, they noted elevations in
body temperature on day 2, fever .40.2uC by day 3, and a
reduction in food intake. A subsequent publication reported
leukopenia and an increase in neutral fats 2–3 days after infection
[14]. In the current report we were able to determine that the major
effect of the infection on white blood cells is due to a depletion of
lymphocytes. Platelet counts were also depleted over the course of
the infection. Therefore, previous reports, coupled with our current
data, strongly suggest that inhalation of F. tularensis in rabbits
constitutes a relevant model of the human disease. Further work is
Figure 4. Increases in erythrocyte sedimentation rate and liver
function markers after inhalation of F. tularensis. Blood samples
collected pre- and post-exposure were analyzed for changes in ESR (A),
cholesterol level (B), and ALT (C). Graphs show values for individual
rabbits (gray circles) and averaged data (black bars) for each time point
after exposure when blood was drawn (days 22, 2, 4, 6, and at
euthanasia).
doi:10.1371/journal.pone.0024654.g004
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to elucidate the pathophysiology of tularemia in rabbits to aid in
determining whether rabbits are a suitable model to meet the
requirements of the Animal Rule.
An additional requirement of the FDA’s Animal Rule for
selection of animal models to use in pivotal efficacy studies is that
the mechanism of amelioration/protection must be the same in
the animal model as in the human. While ethical and logistical
reasons impede the ability to conduct an efficacy study of medical
countermeasures against pneumonic tularemia in humans, there
exists data from studies conducted in the 1950’s and 1960’s that
can be used to guide the selection of an animal model. In
particular, vaccination with the live vaccine strain (LVS) of F.
tularensis by the intracutaneous or aerosol routes induced at least
partial protection in humans against aerosol challenge with the
SCHU S4 strain of F. tularensis; humans were protected against
aerosol challenge with 200–2,000 cfu but not 10-fold higher doses
[3,20,21,22]. A prior report has indicated that vaccination with
LVS increased time to death of rabbits challenged with SCHU S4
(at a dose of 5610
5 cfu ) but no rabbits survived challenge [14]. In
ongoing studies we have found similar results: vaccination with
LVS extended time to death typically by 1–2 days but no
LVS-vaccinated rabbits survived aerosol challenge with SCHU S4
at doses between 1,000–10,000 cfu [23]. In contrast, some rabbits
vaccinated with attenuated mutants of SCHU S4 did survive
aerosol challenge. We believe therefore that the rabbit model will
prove to be a more stringent model of protection than nonhuman
primates or rats but not as rigorous as the mouse model. However,
this will need to be further evaluated before the rabbit can be
accepted as a suitable model for tularemia vaccine efficacy studies.
The animal models most commonly used to study pneumonic
tularemia are mice and nonhuman primates (NHP). Many aspects
of the human disease are recapitulated in these models. There are
concerns about the use of the mouse model as mice are susceptible
to strains of F. tularensis that are attenuated in NHP and humans
and vaccination with LVS poorly protects against respiratory
challenge with F. tularensis [11]. The susceptibility to attenuated
strains suggests that different mechanisms are involved in the
pathogenesis of Francisella infection in mice relative to humans or
other species. Nonhuman primates have generally been considered
good models of human tularemia; however, the FDA’s Animal
Rule has commonly been interpreted to mean that testing in more
than one animal model is necessary to satisfy the FDA’s
requirements for pivotal efficacy studies to support vaccine
licensure. There have also been recent reports detailing tularemia
studies in rats [24,25,26]. Similar to what we report here and prior
Figure 6. Gastrointestinal pathology and hepatosplenomegaly
associated with tularemia in rabbits. Anterioposterior radiographs
showing the abdomen of a single representative rabbit two days prior
(A) and four days after (B) infection with F. tularensis, illustrating gas
production and distension of the intestines and stomach. Pictures of
the small intestines (C), colon (D), spleen (E) and liver (F) examined at
necropsy from a single representative rabbit.
doi:10.1371/journal.pone.0024654.g006
Figure 5. Radiographs and gross pathological changes in lungs
demonstrating development of pneumonic tularemia in rab-
bits. Anterioposterior radiographs (A–C) taken of three anesthetized
rabbits four days after infection with F. tularensis illustrating develop-
ment of bilaterial pneumonia. Arrows on radiographs indicate presence
of air bronchograms. Pictures of the lungs removed from those same
three rabbits at necropsy on day 5 (D,E) or day 6 (F) after infection.
doi:10.1371/journal.pone.0024654.g005
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reported in humans and are resistant to inoculation with LVS.
Therefore, there is a need to explore both rats and rabbits as
alternative models of pneumonic tularemia to comprehensively
test the efficacy of vaccines against this disease.
The current work suggests that rabbits also constitute a valuable
model as they reproduce the key pathophysiological aspects of the
human disease. In addition to showing similar gross pathology to
humans infected with virulent F. tularensis, rabbits are resistant to
LVS [14,15]. However, although vaccination of rabbits with
LVSlengthened survival of these animals relative to unvaccinated
controls after aerosol challenge with SCHU S4 (at a high dose) it
does not prevent death [14]. Thus, further studies characterizing
the immunologic response of rabbits to F. tularensis will be
necessary to definitively establish the value of rabbits as a model
for vaccine efficacy in pneumonic tularemia.
Materials and Methods
Rabbits
Young female New Zealand White (NZW) rabbits were
obtained from Myrtle’s Rabbitry (Thompsons Station, TN) and
housed in the University of Pittsburgh Regional Biocontainment
Laboratory (RBL) at ABSL-3 for the duration of the studies. Prior
to exposure, IPTT-300 temperature/ID chips (BioMedic Data
Systems, Seaford, DE) were implanted subcutaneously. Temper-
ature was read using a DAS-7000 reader (BioMedic Data
Systems). Food and water intake was monitored and recorded
twice daily. All studies were approved by the University of
Pittsburgh’s Institutional Animal Care and Use Committee,
protocol number 1004196. The University of Pittsburgh is an
AALAC-approved facility.
Bacteria
Virulent F. tularensis strain SCHU S4 was used in these studies.
A stock was prepared by one in vitro passage of an isolate obtained
from Dynport Vaccine Company (Frederick, MD). This stock was
washed one time and frozen at
280uC in Brain Heart Infusion
broth (BHI) containing 20% glycerol. For aerosol exposures,
SCHU S4 was streaked on cysteine heart agar (CHA) containing
1% hemoglobin and incubated for 2 days at 37uCi n5 %C O 2.
Individual colonies were picked off the plate and resuspended in
PBS to an OD600 reading of 0.1; 0.5 ml of diluted SCHU S4 was
added to a baffled polycarbonate vented 125 ml flask containing
24.5 ml of BHI. The flask was placed in a shaking incubator and
incubated overnight at 37uC. At approximately 18 h after the
culture was started, it was removed from the shaker and the OD
read at 600 nm. Using a growth curve from prior studies, the
concentration was adjusted in BHI to the concentration desired
for aerosol exposures. During preparation and throughout the
exposures, F. tularensis was kept on ice. After the exposures were
completed, samples of the nebulizer and all-glass impinger (AGI)
contents were diluted 10-fold in PBS, spread on quad CHA plates
in duplicate and incubated at 37uC5 %C O 2 for 2 days prior to
counting.
Aerosols
Aerosols were conducted inside a class III biological safety
cabinet (Baker Co., Sanford, ME) located inside the aerobiology
suite of the University of Pittsburgh Regional Biocontainment
Laboratory (RBL). Animals are transported from their holding
room to the aerobiology suite via mobile transfer carts (Baker).
Rabbits were exposed two at a time for 10 minutes in a nose-only
exposure chamber (CH Technologies, Westwood, NJ) while
plethysmography data was collected in real-time using Buxco
XA software (Buxco Research Systems, Wilmington, NC) during
the exposure. Aerosols were created with a vertical discharge 3-jet
Collison nebulizer controlled by the AeroMP aerosol management
platform (Biaera Technologies, Hagerstown, MD). Aerosol
samples were collected using an all-glass impinger (AGI)
containing 10 ml of BHI and 0.001% Antifoam A (Sigma-Aldrich,
St. Louis, MO) operating at 6 lpm for the duration of the
exposure. At the conclusion of the aerosol, the system was purged
with clean air for 5 minutes after which the rabbits were
transported back to their holding room. Aerosol concentration
was determined was described previously: the bacterial count
measured in the AGI was multiplied by the volume of liquid in the
AGI which was then divided by the product of the flow of air
through the AGI and the duration of the exposure [19]. Inhaled
(presented) dose was also determined as described previously: the
aerosol concentration multiplied by the rabbit’s minute volume
and the duration of the exposure [19].
Phlebotomy and X-rays
Rabbits were anesthetized first by subcutaneous injection of
ketamine (80 mg/kg) and xylazine (8 mg/kg). Isoflurane (dose)
was used to maintain anesthesia while the rabbit was bled via
the ear vein. Approximately 2 ml of blood was collected per
procedure; a portion was used for clinical chemistries, for
bacteremia, and for erythrocyte sedimentation rate, and for
measurement of antibody titers. Once phlebotomy was completed
the rabbit was laid prone and lateral and chest digital x-rays were
taken (Kodak). The xylazine was reversed by i.m. injection of dose
(mg/kg) yohimibine. The rabbit was returned to its cage and
monitored until it recovered from anesthesia.
Monitoring
Rabbits were monitored twice daily after exposure. Body weight
was recorded once in the morning and body temperature was
recorded twice daily. A clinical scoresheet was used to record body
temperature and changes in weight, behavior and appearance.
Figure 7. Bacterial load in organs of rabbits that succumbed to
pneumonic tularemia. Samples of the spleen, liver, and lungs were
homogenized, diluted in PBS and plated on CHA to determine bacterial
load in rabbits. Graph shows log10 data for individual rabbits that were
either euthanized (filled triangles) or found dead (open triangles).
doi:10.1371/journal.pone.0024654.g007
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Temperature: .34uC and ,40uC=1; .40=2; .41=3;
.42=4; .32 & ,34=5; ,32=euthanize promptly. Weight
Loss: up to 10%=1; 11–15%=2; 16–20%=3; 21–25%=4;
.25% euthanize promptly. Appearance: Normal=1; reduced
grooming=2; ruffled fur=3; hunched=4; respiratory distress=5.
Behavior: Normal=1; less peer interaction=2; huddled=3;
moving only when prodded=4; no response=5. Monitoring
was increased to every six hours if an animal’s score was 12 or
higher and if the score reached 15 or higher the rabbit was
considered moribund and was euthanized promptly. Food and
water intake was recorded separately. When rabbits reached a
score at which they were considered to be moribund, they were
promptly euthanized.
Euthanasia and necropsy
Rabbits were euthanized by intravenous injection of sodium
pentobarbital at 100 mg/kg. Once death was confirmed rabbits
were necropsied. Pictures were taken of organs removed from the
rabbits and samples of the liver, spleen and lung were taken for
determining bacterial loads.
Erythrocyte Sedimentation Rates
Rabbit whole blood collected in EDTA was pipetted using a
glass Pasteur pipet into glass Wintrobe tubes. After one hour, the
degree of sedimentation was recorded in mm for each rabbit.
Hematology
Rabbit whole blood collected in EDTA was analyzed on a
VetScan HM2 (Abaxis, Union City, CA) to determine the
complete blood count and on a VetScan VS2 (Abaxis) to measure
blood chemistry, using a profile optimized for mammalian liver
function.
Statistical methods
Data was collected and organized using spreadsheets in
Microsoft Excel 2007; analysis was conducted using a two-tailed
Student’s t-test available in the Analysis Toolpak add-in.
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